目的探讨不同剂量复方倍他米松用于皮内阻滞治疗带状疱疹后神经痛(PHN)的安全性和有效性。方法将2013年6月-2014年12月收治的符合要求的老年PHN患者96例,随机均分为生理盐水对照组(C组)、复方倍他米松0.5 m L组(B0.5组)和复方倍他米松1....目的探讨不同剂量复方倍他米松用于皮内阻滞治疗带状疱疹后神经痛(PHN)的安全性和有效性。方法将2013年6月-2014年12月收治的符合要求的老年PHN患者96例,随机均分为生理盐水对照组(C组)、复方倍他米松0.5 m L组(B0.5组)和复方倍他米松1.0 m L组(B1.0组)。C组镇痛液配方:2%利多卡因5 m L+生理盐水配成20 m L溶液;B0.5、B1.0组配方分别是在C组配方中加入0.5、1.0 m L的复方倍他米松。同组患者于治疗的第1、8、15天皮内注射1次相同配方的镇痛液。所有患者治疗过程口服相同药物。记录患者治疗前、出院时、出院后3个月视觉模拟评分(VAS)、睡眠质量评分(QS)和治疗期间的不良反应。结果 C组1例、B1.0组2例患者退出研究。出院时和出院后3个月时,3组患者VAS、QS均较治疗前明显改善,差异有统计学意义(P<0.05);B0.5、B1.0组VAS、QS较C组明显改善,差异有统计学意义(P<0.05);B0.5、B1.0组间VAS和QS差异无统计学意义(P>0.05)。结论皮内阻滞治疗PHN的20 m L镇痛液中加入0.5或1.0 m L复方倍他米松可明显减轻患者疼痛程度、改善患者睡眠质量;皮内阻滞治疗PHN的20 m L镇痛液中加入复方倍他米松0.5 m L较1.0 m L更合理。展开更多
Hypertension is a leading cause of mortality and morbidity around the world and,prevalence of hypertension is increasing with aging.Hypertension in the elderly is associated with increased occurrence rates of sodium s...Hypertension is a leading cause of mortality and morbidity around the world and,prevalence of hypertension is increasing with aging.Hypertension in the elderly is associated with increased occurrence rates of sodium sensitivity,isolated systolic hypertension,and 'white coat effect'.Arterial stiffness and endothelial dysfunction also increase with age.These factors should be considered in selecting antihypertensive therapy.The prime objective of this therapy is to prevent stroke.The fmdings of controlled trials show that there should be no cut-off age for treatment.A holistic program for controlling cardiovascular risks should be fully discussed with the patient,including evaluation to exclude underlying causes of secondary hypertension,and implementation of lifestyle measures.The choice of antihypertensive drug therapy is influenced by concomitant disease and previous medication history,but will typically include a thiazide diuretic as the first-line agent;to this will be added an angiotensin inhibitor and/or a calcium channel blocker.Beta blockers are not generally recommended,in part because they do not combat the effects of increased arterial stiffness.The hypertension-hypoten-sion syndrome requires case-specific management.Drug-resistant hypertension is important to differentiate from faulty compliance with medication.Patients resistant to the third-line drug therapy may benefit from treatment with extended-release isosorbide mononitrate.A trial of spironolactone may also be worthwhile.展开更多
文摘目的探讨不同剂量复方倍他米松用于皮内阻滞治疗带状疱疹后神经痛(PHN)的安全性和有效性。方法将2013年6月-2014年12月收治的符合要求的老年PHN患者96例,随机均分为生理盐水对照组(C组)、复方倍他米松0.5 m L组(B0.5组)和复方倍他米松1.0 m L组(B1.0组)。C组镇痛液配方:2%利多卡因5 m L+生理盐水配成20 m L溶液;B0.5、B1.0组配方分别是在C组配方中加入0.5、1.0 m L的复方倍他米松。同组患者于治疗的第1、8、15天皮内注射1次相同配方的镇痛液。所有患者治疗过程口服相同药物。记录患者治疗前、出院时、出院后3个月视觉模拟评分(VAS)、睡眠质量评分(QS)和治疗期间的不良反应。结果 C组1例、B1.0组2例患者退出研究。出院时和出院后3个月时,3组患者VAS、QS均较治疗前明显改善,差异有统计学意义(P<0.05);B0.5、B1.0组VAS、QS较C组明显改善,差异有统计学意义(P<0.05);B0.5、B1.0组间VAS和QS差异无统计学意义(P>0.05)。结论皮内阻滞治疗PHN的20 m L镇痛液中加入0.5或1.0 m L复方倍他米松可明显减轻患者疼痛程度、改善患者睡眠质量;皮内阻滞治疗PHN的20 m L镇痛液中加入复方倍他米松0.5 m L较1.0 m L更合理。
文摘Hypertension is a leading cause of mortality and morbidity around the world and,prevalence of hypertension is increasing with aging.Hypertension in the elderly is associated with increased occurrence rates of sodium sensitivity,isolated systolic hypertension,and 'white coat effect'.Arterial stiffness and endothelial dysfunction also increase with age.These factors should be considered in selecting antihypertensive therapy.The prime objective of this therapy is to prevent stroke.The fmdings of controlled trials show that there should be no cut-off age for treatment.A holistic program for controlling cardiovascular risks should be fully discussed with the patient,including evaluation to exclude underlying causes of secondary hypertension,and implementation of lifestyle measures.The choice of antihypertensive drug therapy is influenced by concomitant disease and previous medication history,but will typically include a thiazide diuretic as the first-line agent;to this will be added an angiotensin inhibitor and/or a calcium channel blocker.Beta blockers are not generally recommended,in part because they do not combat the effects of increased arterial stiffness.The hypertension-hypoten-sion syndrome requires case-specific management.Drug-resistant hypertension is important to differentiate from faulty compliance with medication.Patients resistant to the third-line drug therapy may benefit from treatment with extended-release isosorbide mononitrate.A trial of spironolactone may also be worthwhile.